Skip to main content
. 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465

Figure 1.

Figure 1

The incidence of primary resistance to immunotherapy in NSCLC patients. The highest incidence of primary resistance to ICIs was found in patients treated with ICIs as second-line treatment after chemotherapy failure, while the lowest incidence was found in NSCLC patients previously treated with immunotherapy plus chemotherapy.